Programs

Home/Programs

Day 1 : Jun 01,2026
Day 1
Agenda Download
Keynote Speakers
Biography:
Prof. Ali Soofastaei is a technology leader specializing in AI-driven digital transformation, data governance, and large-scale analytics. He has led global programs across asset-intensive industries, designing production-grade data platforms, decision-support systems, and MLOps frameworks that improve safety, reliability, and sustainability. Ali holds a PhD in Information Technology (University of Queensland) and an MEng in Systems Engineering (Johns Hopkins University). His work focuses on translating complex, heterogeneous data into actionable, transparent decisions using modern data products, value-driver trees, and explainable machine learning (e.g., SHAP-based analyses). A frequent keynote speaker and author, he partners with executives and multidisciplinary teams to operationalize AI responsibly—linking models to measurable outcomes and robust governance. His current interests include privacy-preserving learning, energy-aware analytics for healthcare facilities, and resilient architectures for real-time clinical and laboratory operations.

Abstract:
Healthcare and bioscience are entering a data-dense era shaped by connected devices, high-throughput laboratories, and digitized clinical workflows. Yet many organizations still struggle to turn heterogeneous data into trustworthy, operational decisions. This talk distills practical lessons from large-scale digital transformation in asset-intensive industries—where safety, reliability, sustainability, and cost discipline must coexist—and maps them to healthcare and bioscience use cases. I will outline a repeatable architecture for predictive and prescriptive analytics that integrates streaming telemetry (wearables, laboratory instruments, building management systems), transactional systems (EHR/LIMS/ERP), and unstructured data (clinical notes, imaging metadata). The approach emphasizes: (1) governed data products with clear ownership and quality SLAs; (2) value-driver trees that translate models into measurable clinical, operational, and sustainability outcomes; (3) robust MLOps for deployment, monitoring, and drift management; and (4) human-centered change management to secure adoption. Methodologically, I will cover forecasting and anomaly detection for patient flow and equipment uptime; classification and ranking for triage and imaging worklists; and reinforcement-learning-style policies for resource scheduling. Model transparency is addressed using explainability techniques (e.g., SHAP summaries at cohort and case levels) and lineage/audit trails to satisfy regulatory and ethical requirements. I will also discuss privacy-preserving patterns (federated/edge training), bias assessment, and governance checkpoints. Illustrative vignettes include: predictive maintenance for critical laboratory and imaging assets; dynamic staffing and theatre scheduling using time-series demand signals; and energy-aware facility control that reduces environmental footprint without compromising patient safety. The session concludes with a pragmatic playbook—maturity assessment, opportunity discovery, minimum viable model, guarded pilot, and scaled rollout—backed by templates and metrics that attendees can adapt to their contexts. The core message is simple: by combining disciplined data governance with explainable, operations-aware AI, healthcare and bioscience organizations can move beyond dashboards to decisions—safely, sustainably, and at scale.
Speaker Sessions
Biography:
Dr. Sonia Ruiz is a dietitian-nutritionist and holds a doctorate from Ramon Llull University, specializing in digestive disorders and weight management. She earned her diploma in Dietetics and Human Nutrition at the same university and has completed advanced training in her specialty at national and international institutions. She is the author of three books on nutrition and a prominent science communicator, participating in television programs, radio shows, magazines, and conferences to make nutrition science accessible to the general public. In her professional practice, she combines nutritional education with personalized strategies for digestive disorders, intestinal dysbiosis, intolerances, and obesity, offering both in-person and international virtual consultations. She has developed dietary methods focused on sustainable habits, promoting nutrition based on scientific evidence and tailored to each individual.

Abstract:
Introduction: Giardiasis, caused by Giardia lamblia, is a common intestinal infection that can lead to chronic diarrhea, malabsorption, bloating, and fatigue. Its impact on gut microbiota and the digestive metabolism of fats and proteins remains poorly studied. This study is among the first to correlate microbial profiles with digestive symptoms and specific metabolites (bile acids and SCFAs), providing evidence for personalized therapeutic strategies.
Objectives: To characterize common alterations in the gut microbiota of patients with giardiasis and correlate them with digestive and metabolic symptoms, including chronic diarrhea, steatorrhea, intestinal inflammation, and opportunistic fungal overgrowth.
Methods: Microbiota reports from eight patients were analyzed using NGS at Teletest. Bacillota/Bacteroidota and Firmicutes/Bacteroidetes ratios, bile acids and SCFA levels, proteolytic bacteria (Clostridium spp., Fusobacterium, Desulfovibrio), opportunistic fungi (Fusarium, Neurospora), and inflammation markers (FOB, calprotectin) were assessed. Recurring patterns were identified and correlated with clinical symptoms to establish relationships between microbiota, metabolites, and digestive manifestations.
Results: All patients showed gut dysbiosis, with significant alterations in Bacillota/Bacteroidota and Firmicutes/Bacteroidetes ratios. Secondary bile acids (DCA, LCA) and SCFAs were reduced, associated with steatorrhea in three patients. Five patients showed increased proteolytic bacteria, correlated with bloating, gas, and slow protein digestion. Intestinal inflammation was evident with elevated calprotectin in four patients and positive FOB in three, indicating mucosal damage. Additionally, three patients exhibited opportunistic fungal overgrowth, mainly Fusarium and Neurospora, linked to excessive fermentation and abdominal distension. Severe cases presented combinations of extreme dysbiosis, marked inflammation, and persistent symptoms, including chronic diarrhea, fatigue, and nutrient malabsorption.
Conclusions: Chronic giardiasis significantly alters gut microbiota, impairs fat and protein digestion, promotes inflammation, and favors fungal overgrowth. Patients with more severe alterations experience persistent symptoms and greater dysbiosis. These findings highlight the need for therapies aimed at restoring microbial balance and digestive function, supporting the potential of personalized treatments based on gut ecosystem modulation.
Abstract:
Background: Achieving Universal Health Coverage (UHC) requires accessible, accurate, and patient centered diagnostic tools. Traditional anthropometric methods are often limited, particularly for critically ill or immobile patients, creating barriers to quality care. The InBody S10, a medical-grade body composition analyzer, applies direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) to provide precise measurements of intracellular water (ICW), extracellular water (ECW), total body water (TBW), muscle mass, and fat distribution.

Objective: To evaluate the clinical utility of the InBody S10 in enhancing patient-centered clinical nutrition assessment and guiding evidence-based management across diverse care settings, thereby strengthening health systems in line with UHC and Sustainable Development Goals (SDG) 2030.

Methods: The InBody S10 was applied in outpatient clinics, dialysis unit, paediatrics unit, medical ward, surgical ward, and intensive care unit at Mama Lucy Kibaki Hospital. Assessments were conducted with patients seated, lying, or standing. Outputs such as ECW/TBW ratio, protein mass, mineral mass, body fat mass, Visceral Fat Analysis (VFA), TBW/FFM, Skeletal Muscle Index (SMI), phase angle, and segmental lean mass informed interventions, including dialysis adjustment, nutrition therapy, sarcopenia monitoring, and rehabilitation planning.

Results:
The technology facilitated early detection of malnutrition and fluid imbalance, enabling precision interventions. ECW/TBW ratios flagged edema and dialysis inefficiencies; phase angle values guided prognosis in oncology and geriatrics and other cases; segmental lean mass data supported physiotherapy and rehabilitation. Portability and reproducibility enhanced uptake in routine care. Challenges included the need for capacity building in interpretation and integration into electronic medical records.

Conclusion : The InBody S10 represents an innovation and technology in health that strengthens patient management, supports personalized care, and improves health outcomes. Its wider adoption across countries could contribute significantly to population health and health system strengthening, accelerating progress toward UHC and SDG 3 (Good Health and Well-being).
Biography:
Wejdan Abdullah Khubrani, passionate about clinical nutrition, community health, and evidence-based practice. I have led multiple health initiatives and teams that focus on nutrition education, patient awareness, and public well-being. As an inventor, I developed an innovative patent-pending system that measures and analyzes nutrient intake using smart technology. My work reflects strong leadership, creativity, and a deep commitment to advancing the field of nutrition and health innovation.

Abstract:
This study explores how popular matcha has become among women in Saudi Arabia and what drives this growing trend. Findings reveal that many consume matcha for its perceived health and weight-loss benefits, yet few are aware of its caffeine content and possible side effects. The research emphasizes the need for evidence-based nutrition awareness to support informed dietary choices. Our aim to assess the prevalence, motivations, and awareness levels .related to matcha consumption among women in Saudi Arabia Methodology: A descriptive cross-sectional study was conducted using an online questionnaire distributed among Saudi women of different age groups. Data were analyzed to determine patterns, motivations, and awareness about matcha tea consumption.

The results showed that a significant portion of participants consumed matcha for weight management and energy improvement. However, awareness regarding its caffeine content and potential side effects was relatively low. The findings highlight a knowledge gap between perception and evidence-based understanding. Conclusion Matcha consumption among Saudi women is increasing, largely due to social media trends and perceived health benefits. Promoting nutrition education can help ensure safe and informed consumption.
Biography:
Haylen J. Marín G. is a Spain-based Internal Medicine specialist with cross-system clinical experience in Venezuela, Ecuador, and Spain, where she currently practices at Hospital Universitario San Agustín de Linares (Andalusia). Trained at Universidad Central de Venezuela and homologated in Spain in 2017, she holds a Master's in Infectious Diseases (Universidad Rey Juan Carlos I, 2023) and is completing a Master's in Inborn Errors of Metabolism (Universidad de Santiago de Compostela, 2024–2025). Her clinical and academic work focuses on the intersection between rare metabolic diseases and the inflammatory mechanisms shared with common cardiometabolic disorders. In 2025 she published, as first author, a longitudinal immuno-genetic analysis of systemic inflammation in Fabry disease (Therapeutic Advances in Rare Disease), proposing an inflammatory phenotype-based framework beyond enzyme replacement. She is an active speaker at SEMI and international rare-disease forums, and author of Metabolismo Emocional (Arcopress/Almuzara, 2026), a science-communication book on metabolism and inflammation

Abstract:
Common obesity is still widely framed as a behavioral failure, despite robust evidence that it is a disorder of energy homeostasis with a strong inflammatory component. This narrative gap delays diagnosis, fuels stigma, and obscures the fact that obesity sits on a biological continuum where rare metabolic diseases occupy the most informative extreme. The clinical question this lecture addresses is straightforward: what can the orphan end of metabolism teach us about the pathophysiology — and the treatment — of the common one? Conceptual Framework & Theoretical Orientation: The talk uses rare metabolic diseases as a natural laboratory to expose the molecular circuits perturbed in polygenic obesity. Three convergent axes are integrated: (1) the leptin–melanocortin pathway, where defects in LEP, LEPR, POMC, PCSK1, and MC4R produce hyperphagia and early-onset obesity; (2) lipodystrophies, where the failure of safe adipose expansion drives ectopic lipid deposition, severe insulin resistance, and metaflammation; and (3) the NLRP3 inflammasome–IL-1? axis, activated by lipotoxic ceramides and danger signals, which links adipose stress to systemic metabolic disease. Key Insights: Each rare disease exposes a node that is also operative — more subtly and in combination — in common obesity. Setmelanotide, an MC4R agonist approved by the FDA in 2020 and progressively expanded through 2025 to additional monogenic, syndromic, and acquired hypothalamic obesities, validates the leptin–melanocortin axis as a druggable target and offers a working template for pathway-specific obesity therapeutics beyond incretin-based agents. Lipodystrophy and inflammasome biology, in turn, anchor the adipose-tissue and metaflammation narrative that increasingly informs cardiometabolic risk stratification. Conclusion & Significance: Reframing obesity as a continuum of adipose maladaptation and metaflammation — anchored mechanistically by rare disease — sharpens phenotyping, dignifies the patient, and accelerates precision obesity medicine. For clinicians, researchers, and industry, the orphan perspective is not a curiosity: it is a translational shortcut.
Biography:
Dr. Maite Iglesias Badiola holds a PhD in Molecular Biology from the Autonomous University of Madrid, Spain. She completed postdoctoral research at the National Cancer Institute (NIH, USA), focusing on HPV and cervical cancer progression, and later conducted research at the CSIC in Madrid on epithelial carcinogenesis. Since 2000, she has been a teaching researcher at Universidad Francisco de Vitoria (UFV), where she launched innovative educational programs and the 3Eras Rare Diseases School. She has received two national research recognitions (CNEAI) and published extensively in high-impact international journals. Currently, she is Dean of the Faculty of Experimental Sciences and a Full Professor of Research Methodology, leading a research group in stem cells and regenerative medicine, with a focus on neuronal regeneration in the central nervous system.

Abstract:
Human placental-derived amniotic stromal cells (hAMSCs) have emerged as versatile agents in regenerative medicine due to their immunomodulatory properties, ease of isolation, and secretion of bioactive factors. This work presents two complementary lines of research that demonstrate their therapeutic potential in both neurodegenerative and cardiovascular diseases. In the neurological domain, hAMSCs have been shown to promote regeneration of injured retinal ganglion cells (RGCs) in rats, enhancing axonal growth (19–26 ?m/neuron) and restoring electrophysiological activity under normoxic and hypoxic conditions. Transwell and conditioned medium experiments confirmed that these effects are mediated by paracrine mechanisms involving neurotrophic factors such as BDNF, NGF, and NT-3. Patch clamp recordings validated the functional recovery of regenerated neurons, demonstrating action potential firing. Current investigations focus on placental-derived exosomes, which retain the bioactive properties of the source tissue and offer a promising avenue for personalized medicine. These nanovesicles modulate key cellular processes including inflammation, apoptosis, and regeneration, and are particularly effective in neurodegenerative conditions such as glaucoma. In the cardiovascular context, hAMSCs were evaluated in a murine model of myocardial ischemia/reperfusion (I/R). Intravenous administration of hAMSCs two days post-I/R significantly improved left ventricular ejection fraction (64.5% vs. 50.0% in controls) and reduced myocardial necrosis and fibrosis. Despite minimal direct cellular engraftment, a paracrine mechanism was identified involving extracellular vesicles (EVs) carrying miR-150. This microRNA regulates the MIAT/miR-150/Hoxa4 axis, which is critical for cardioprotection. CRISPR-Cas9 mediated deletion of miR-150 in hAMSCs abolished the therapeutic effect, while administration of purified EVs or lipid nanoparticles containing miR-150 replicated the observed benefits. These findings position hAMSCs as a multimodal therapeutic platform capable of addressing complex pathologies through targeted paracrine signaling and highlight the potential of exosome-based interventions in future regenerative therapies.  
Biography:
Dr. Anand Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. Dr. Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals. Furthermore, Dr. Srivastava’s expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the “Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. Based on his extraordinary scientific achievements his biography has been included in “WHO IS WHO IN AMERICA” data bank two times, first in 2005 and second in 2010.

Abstract:
The experimental evidences strongly suggest that embryonic stem (ES) cell lines can be created from human blastocyst-stage embryos and stimulated to develop into practically all types of cells found in the body. Cellular treatments produced from ES cells have attracted fresh interest. The potential utility of ES cells for gene therapy, tissue engineering, and the treatment of a wide spectrum of currently untreatable diseases is simply too vital to ignore; however, further improvements in our understanding of the basic biology of ES cells are required to deliver these forms of therapy in a safe and efficient manner. In this meeting, I'll share my research using ES cells and how they can be used to treat hematopoietic and neurodegenerative disorders. 
Abstract:
With increasing life expectancy, the clinical demand for regenerative therapies in dentistry—particularly for jawbone reconstruction prior to dental implant placement—is steadily rising.1 Despite significant advances in regenerative medicine, the use of adult stem cells derived from dental tissue waste presents several challenges in clinical translation.2 To identify the most suitable cell source for e.g. alveolar bone regeneration, stem cells from diverse origins have been systematically compared. Furthermore, a novel regenerative strategy has been developed that integrates biomaterial scaffolds, synthetic ligands targeting purinergic receptors—known to promote osteogenesis and angiogenesis—with mesenchymal stem cells.3 Stem cells isolated from cortical and corticocancellous bone chips were characterized by the expression of standard mesenchymal stem cell markers (CD73, CD90, CD105) and subsequently evaluated for their osteogenic differentiation potential.4 These cells were compared with mesenchymal stem cells from other sources and stem cells derived from wisdom teeth. In an in vitro model, a defined set of synthetic and natural ligands for P2 purinergic receptors was employed to enhance both osteogenic and angiogenic responses. Preoperative antibiotic treatment significantly improved the viability of bone chip-derived stem cells. Notably, osteogenic differentiation capacity was independent of the quantity and species of detected microorganisms.4 Intriguingly, stem cells originating from cranial regions—derived from the pharyngeal (brachial) arch exhibited a pronounced pre-commitment toward osteogenic lineage differentiation when compared to stem cells from somite-derived tissues. Based on these findings, a stepwise regenerative approach is proposed: first, ectomesenchymal stem cells are differentiated into osteoblasts on a scaffold system, followed by the application of a specific purinergic receptor ligand or exosomes to stimulate angiogenesis, if required.5 This integrated strategy — combining cell-based therapy, bioactive signaling molecules, and biomaterial scaffolds — holds significant promise for the future of jawbone reconstruction in clinical dentistry.
Biography:
Hari Shanker Sharma, FRSM (UK), is Director of Research (Int. Expt. ECNSIR) and Professor of Neurobiology at Uppsala University, Sweden, affiliated with the Department of Surgical Sciences, Division of Anesthesiology and Intensive Care. Born in Dalmianagar, India (1955), he earned his B.Sc. (Hons) from L.S. College Muzaffarpur in 1973. Dr. Sharma’s pioneering research on the blood-brain barrier and brain edema led to his title of Docent in Neuroanatomy at Uppsala University (2004). His main interests are neuroprotection and neuroregeneration in stress, trauma, and drug abuse. He has received prestigious awards including the Laerdal Foundation Award (2005), NIDA Distinguished Scientist Award (2006–08), Best Investigator Award (2008), and the Dr. Anthony Marmarou Award (2011). With over 30 years of research, he has authored books, edited volumes, and serves on editorial boards of numerous international journals. Dr. Sharma is also a member of renowned academies, including the New York Academy of Sciences.

Abstract:
dl-3-n-butylphthalide (dl-NBP) is one of the potent antioxidant compounds induce profound neuroprotection in stroke and traumatic brain injury. Our previous studies show that dl-NBP reduces brain pathology in Parkinson’s disease (PD) following its nanowired delivery together with mesenchymal stem cells (MSCs) exacerbated by concussive head injury (CHI). CHI alone elevates alpha synuclein (ASNC) in brain or cerebrospinal fluid (CSF) associated with elevated TAR DNA-binding protein 43 (TDP-43). TDP-43 protein is also responsible for the pathologies of PD. Thus, it is likely that exacerbation of brain pathology in PD following brain injury may be thwarted using nanowired delivery of monoclonal antibodies (mAb) to ASNC and/or TDP-43. In this review the co-administration of dl-NBP with MSCs and mAb to ASNC and/or TDP-43 using nanowired delivery in PD and CHI induced brain pathology is discussed based on our own investigations. Our observations show that co-administration of TiO2 nanowired dl-NBP with MSCs and mAb of ASNC or TDP-43 induced superior neuroprotection in CHI induced exacerbation of brain pathology in PD, not reported earlier. 
Biography:
Aruna Sharma (née Bajpai) is a Medical Administrator at Uppsala University Hospital. After graduating in Indian Medicine, she pursued advanced training at Free University Berlin and University Hospital Klinikum Steglitz (1989–1991). She joined the Department of Surgical Sciences in 2004 and has since focused on nanoneurotoxicity, studying the effects of engineered metal nanoparticles and silica dust in brain injury and stress models, supported by EOARD, London. Her research was recognized at the Society for Neuroscience (2011). She is a member of the Swedish Academy of Pharmaceutical Sciences and has served as editor for leading neuroscience journals, contributing significantly to nanoneuroscience.

Abstract:
Blast brain injury (bBI) following explosive detonations in warfare is one of the prominent causes of multidimensional insults to the central nervous and other vital organs injury. Several military personnel suffered from bBI during Middle East conflict at hot environment. The bBI largely occurs due to pressure waves, generation of heat together with release of shrapnel and gun powders explosion with penetrating and/or impact head trauma causing multiple brain damage. As a result, bBI induced secondary injury causes breakdown of the blood-brain barrier (BBB) and edema formation that further results in neuronal, glial and axonal injuries. Previously we reported endocrine imbalance and influence of diabetes on bBI induced brain pathology that was significantly attenuated by nanowired delivery of cerebrolysin in model experiments. Cerebrolysin is a balanced composition of several neurotrophic factors and active peptide fragments is capable of neuroprotection several neurological insults. Exposure to heat stress alone causes BBB damage, edema formation and brain pathology. Thus, it is quite likely that hot environment further exacerbates the consequences of bBI. Thus, novel therapeutic strategies using nanodelivery of stem cell and cerebrolysin may further enhance superior neuroprotection in bBI at hot environment. Our observations are the first to show that combined nanowired delivery of mesenchymal stem cells (MSCs) and cerebrolysin significantly attenuated exacerbation of bBI in hot environment and induced superior neuroprotection, not reported earlier. The possible mechanisms of neuroprotection with MSCs and cerebrolysin in bBI are discussed in the light of current literature.
Biography:
Dr. Mònica Mir received the Degree in Chemistry from University Rovira i Virgili, Spain in 1998. In 2006 she received her PhD in biotechnology in the same University. She realized different predoctoral stages at the Institute of Microelectronic in Demokritos, University of Bath and National Hellenic Research Foundation. From 2007, she held a postdoctoral position in Max Planck Institute for Polymer Research, Germany. Since 2008, she joins the Institute for Bioengineering of Catalonia (IBEC), Spain as Senior CIBER researcher, combined with her teaching as associate professor at the University of Barcelona. Along her carrier she was managing European, National and industrial research projects, supervising PhD ad Master students and collaborating in congresses organization as coordinator and scientific committee. Her main scientific interests are focused on electrochemical biosensor, integrated in lab-on-a-chip and point of care technologies, implantable sensors, and organ-on-a-chip for biomedical applications.

Abstract:
Nanotechnology and nanomedicine is a cutting-edge field that is growing, providing new solutions in different areas. These new technologies in the medical area cover many possibilities for the study, treatment and diagnosis of different diseases in a more efficient and personalized way. A key tool recently developed in biomedical engineering research thanks to this technology are implantable sensors. The development of miniaturized implantable biosensors in the human body has revolutionized the field of medicine in terms of diagnosis, and monitoring of numerous conditions and diseases, such as cardiovascular disorders and metabolic problems. One of the great advances that these sensors have introduced is their ability to monitor clinical data practically in real time, obtaining records of the body's biophysical and biochemical parameters in a continuous way and for extended periods. This talk will present new technologies in implantable sensors specificaally in blood vessels, which allow for continuous monitoring and early detection of diseases. We will show the developments achieved in this area by our research group for different applications, such as monitoring ischemia in fetuses for detection of fetal growth restriction and the detection of biomarkers of heart disease for early diagnosis. Future trends and the advantages and limitations of this technology will be discussed.
Biography:
Dr. Andrew Demian is an Orthodontist with a special interest in clear aligner therapy and dentofacial orthopedics. He graduated from Cairo University, Egypt, in 2017 with an excellent degree and high honors, ranking third in his class. This achievement earned him an observership opportunity at the Medical University of Graz, Austria. He later returned to Egypt to begin his residency in the Orthodontic Department at Cairo University while also serving as a teaching assistant. Dr. Demian completed his Master’s degree focusing on dentofacial orthopedics and further specialized in clear aligners, including directly printed aligner therapy with Graphy.

Abstract:
Background: The aim of the study was to compare the effectiveness of the intra oral technique using Temporary Anchorage Device (TAD) supported class III elastic wear versus the face mask appliance for maxillary protraction which was done following expansion with Alternate Rapid Maxillary Expansion and Constriction (ALT-RAMEC) protocol using Mini-screw assisted rapid maxillary expander (MARME) for treating growing class III patients with maxillary deficiency
Twenty - Four class III growing with Cervical Vertebrae Maturation Stage (CVM) 2-3 with maxillary deficiency treated with the MARME anchored on two palatal mini-screws with a posterior bite plane following an ALT-RAMEC protocol for nine weeks followed by protraction phase for 6 months using intra oral TAD-supported class III elastics in the intervention group and facemask in the control group.
After finishing protraction, Cephalometric measurements were done to assess treatment outcomes.
Results: All patients in the intervention group were successfully treated reaching positive overjet and overbite while three patients in the control group reached only edge to edge relationship because of the patient incompliance. There was significant advancement of A point in both groups with statically insignificant difference between them. There were minimal maxillary dental changes in both groups. However, Mandibular incisors had retroclined slightly more in the control group than in the intervention group but difference was not statistically significant.
Conclusion: The use of MARME following ALT-RAMEC protocol resulted in maxillary advancement even before starting the protraction. The null hypothesis is accepted as when comparing the results of both groups, there was statically insignificant difference between them in correcting such malocclusion. Use of Intraoral device with help of TAD-supproted class III elastic wear is suitable alternative to extraoral conventional facemask for treating growing skeletal class III patients with maxillary deficiency
Moderator
Biography:
Dr. Cheryl Roche Alexander, DNP, EMBA, is a healthcare strategist, biopharmaceutical executive, and founder of Enlightened Consulting and Dr. Cheryl. Her work bridges biopharma, digital health, patient engagement, population health, value-based care, prevention, and human-centered innovation, with a focus on helping organizations and individuals use technology to improve access, activation, resilience, and outcomes. Across Medical Affairs, Market Access, Commercial, and patient support, she has led and advised initiatives that integrate AI-enabled insights, care coordination, and practical engagement strategies to support earlier identification, treatment, adherence, and patient empowerment. Through Dr. Cheryl, she extends this work into simple self-care systems that help people strengthen physical health, mental clarity, emotional balance, and purpose in an increasingly digital world. As moderator, Cheryl will guide a balanced discussion on how AI, augmented reality, and virtual reality can transform healthcare while requiring thoughtful attention to trust, equity, safety, affordability, and human connection.